MX2021008387A - Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer. - Google Patents

Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer.

Info

Publication number
MX2021008387A
MX2021008387A MX2021008387A MX2021008387A MX2021008387A MX 2021008387 A MX2021008387 A MX 2021008387A MX 2021008387 A MX2021008387 A MX 2021008387A MX 2021008387 A MX2021008387 A MX 2021008387A MX 2021008387 A MX2021008387 A MX 2021008387A
Authority
MX
Mexico
Prior art keywords
cancer
prevention
treatment
monoclonal antibodies
antibodies targeting
Prior art date
Application number
MX2021008387A
Other languages
English (en)
Inventor
David B Weiner
Puchalt Alfredo Perales
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2021008387A publication Critical patent/MX2021008387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se divulga una composición que incluye una secuencia de ácido nucleico recombinante que codifica un anticuerpo o un fragmento de este que se dirige a la proteína 1 de muerte celular programada (PD-1); la divulgación también proporciona un método para prevenir y/o tratar una enfermedad, como cáncer, en un sujeto que usa la composición de la invención.
MX2021008387A 2019-01-11 2020-01-13 Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer. MX2021008387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962791146P 2019-01-11 2019-01-11
PCT/US2020/013286 WO2020146865A1 (en) 2019-01-11 2020-01-13 Dna monoclonal antibodies targeting pd-1 for the treatment and prevention of cancer

Publications (1)

Publication Number Publication Date
MX2021008387A true MX2021008387A (es) 2021-10-13

Family

ID=71520819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008387A MX2021008387A (es) 2019-01-11 2020-01-13 Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer.

Country Status (11)

Country Link
US (1) US20220073614A1 (es)
EP (1) EP3908299A4 (es)
JP (1) JP2022517228A (es)
KR (1) KR20210114976A (es)
CN (1) CN113543800A (es)
AU (1) AU2020207408A1 (es)
BR (1) BR112021013008A2 (es)
CA (1) CA3126073A1 (es)
EA (1) EA202191929A1 (es)
MX (1) MX2021008387A (es)
WO (1) WO2020146865A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
JP7089474B2 (ja) * 2016-01-22 2022-06-22 マブクエスト エスエー 免疫学的試薬
EP3452107A4 (en) * 2016-05-05 2020-04-15 The Trustees of The University of Pennsylvania DNA MONOCLONAL ANTIBODIES AGAINST CHECKPOINT MOLECULES
WO2018069927A1 (en) * 2016-10-10 2018-04-19 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof

Also Published As

Publication number Publication date
EP3908299A1 (en) 2021-11-17
CN113543800A (zh) 2021-10-22
EP3908299A4 (en) 2022-10-05
US20220073614A1 (en) 2022-03-10
JP2022517228A (ja) 2022-03-07
KR20210114976A (ko) 2021-09-24
BR112021013008A2 (pt) 2021-11-23
CA3126073A1 (en) 2020-07-16
EA202191929A1 (ru) 2021-09-23
AU2020207408A1 (en) 2021-07-29
WO2020146865A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2021005708A (es) Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
TW200716743A (en) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2022002682A (es) Anticuerpos anti-cd73.
MX2022013894A (es) Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
WO2021227307A8 (zh) 抗cd73抗体及其用途
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
MX2022009355A (es) Anticuerpo anti-mdr1 y uso del mismo.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
WO2015191590A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
MX2023005386A (es) Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2021008387A (es) Anticuerpos monoclonales de and dirigidos a pd-1 para el tratamiento y prevención de cáncer.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2018013523A (es) Anticuerpos monoclonales de adn dirigidos a il-6 y cd126.
WO2015191610A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
ZA202110285B (en) Antibodies and methods of use
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.